Digital Marketing Trends in Rheumatoid Arthritis

Digital Marketing Trends in Rheumatoid Arthritis

Summary

AbbVie’s Rinvoq.com achieved the highest total traffic across RA patient brand sites in the US, with over four million visitors from February 2022 to January 2023, followed by AbbVie’s Humira.com and Amgen’s Enbrel.com. The highest proportion of traffic to branded patient RA websites originated from organic sources, followed by direct. Cimzia.com and Olumiant.com had the highest proportion of traffic from organic search. Xeljanz.com was supported by the most paid SEO at over 8,700 keywords, while Amgen spent the most on DDA for Enbrel.com, at approximately $3 million.

Amgen's Enbrelpro.com achieved the highest traffic across branded RA HCP sites in the US, with approximately 513,000 visits between February 2022 and January 2023. This was followed by Rinvoqhcp.com, with more than 250,000 visits. For DDA, Amgen spent the most on Enbrelpro.com at approximately $244,000. No notable DDA was detected for other HCP sites. Humirapro.com was supported by the most paid SEO at over 5,135 keywords, followed by Enbrelpro.com (3,685) and Rinvoqhcp.com (1,489).

AbbVie’s RA.com had the highest traffic of all unbranded RA sites in the US, with over 185,000 visitors from February 2022 to January 2023. The highest proportion of traffic to unbranded RA websites in the US originated from direct search, followed by organic and referral traffic. Amgen spent approximately $9,500 on DDA for its Amgeninflammation.com and invested in 9,610 paid SEO keywords. No notable DDA and SEO was detected for other unbranded RA sites in the US.

Between February 2022 and January 2023, 36 social media posts related to RA were detected from pharma companies in the US, including Janssen, Amgen, Eli Lilly, and Bristol Myers Squibb. The post with the highest interaction (2.2%) was from Eli Lilly’s Medical Twitter account highlighting the differences between RA and psoriatic arthritis and the issue of using combination therapy.

AbbVie-care.de in Germany achieved the highest total traffic across branded RA patient sites in EUCAN, with over 700,000 visitors from February 2022 to January 2023. This was followed by Novartis’s Ratgeber-rheuma.de (over 220,000 visits).

Roche's Rhumatismes.net in France had the highest total traffic across RA unbranded sites in EUCAN, with approximately 552,000 visitors between February 2022 and January 2023. This was followed by Pfizer's Hilfefuermich.de (333,000 visitors) and Roche's Rheumahelden.de (50,000 visitors). The highest proportion of traffic originated from organic traffic, followed by direct search and social traffic. Eli Lilly’s Lillyrhumatologie.fr had the highest proportion of organic traffic (91%), while Pfizer's Hilfefuermich.de had the most direct traffic (60%).

Between February 2022 and January 2023, approximately 120 social media posts related to RA were detected from pharma companies in EUCAN, including Sanofi, Pfizer, Eli Lilly, Merck & Co., and AbbVie. The post with the highest interaction (5.3%) was from the AbbVie España Instagram account, which on World Rheumatic Diseases Day 2022 raised awareness of the impact of RA in Spain.

Scope

  • This report assesses key digital marketing metrics of pharma assets in rheumatoid arthritis (RA), including branded websites for patients and healthcare professionals (HCPs), unbranded websites, and social media accounts.
  • Metrics include website traffic volume, engagement, and source, digital display advertising (DDA), paid search engine optimization (SEO), and social media post interaction. Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).
Reasons to Buy
  • Understand the digital marketing competitive landscape in RA, with a view of leading patient and HCP branded assets across different regions.
  • See what tactics pharma companies are using to drive traffic to their RA branded and unbranded assets for patient and HCPs, such as DDA and paid SEO.
  • Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
  • Compare top branded assets for patients by how they address and support different patient needs.
  • See what pharma social media accounts in RA are the most active and achieving the most engagement.


  • Executive Summary
  • US Patient Branded Websites
    • Top US Branded Patient Websites: Total Traffic and Engagement Metrics
    • Top US Branded Patient Websites: Traffic Generation by Source
    • Top US Branded Patient Websites: Paid SEO and DDA Spend
    • Top US Branded Patient Websites: DDA Publisher Breakdown
    • Top US Branded Patient Websites: Highest Spend Ads, Impressions, and Messaging
    • Top US Branded Patient Websites: Feature Comparison
  • US HCP Branded Websites
    • Top US Branded HCP Websites: Total Traffic and Engagement Metrics
    • Top US Branded HCP Websites: Traffic Generation by Source
    • Top US Branded HCP Websites: Paid SEO and DDA Spend
    • Top US Branded HCP Websites: DDA Publisher Breakdown
    • Top US Branded HCP Websites: Highest Spend Ads, Impressions, and Messaging
  • US Unbranded Websites
    • Top US Unbranded Websites: Total Traffic and Traffic Source
  • US Social Media
    • US Social Media Activity in RA
  • EUCAN Branded Websites
    • Top EUCAN Branded Websites: Total Traffic and Engagement Metrics
  • EUCAN Unbranded Websites
    • Top EUCAN Unbranded Websites: Total Traffic and Traffic Source
  • EUCAN Social Media
    • EUCAN Social Media Activity in RA
  • Appendix
    • Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings